Utilizing immune checkpoints and angiogenesis together has proven to be an effective strategy as a therapy for multiple forms of cancer. An open-label, multicenter, phase 2 study was conducted by Qu Y, Sun Z, Han W, et al on camrelizumab and famitinib in eight different cohorts of genitourinary or gynecological cancers. It reviewed the findings of the cohort for advanced or metastatic urothelial carcinoma with platinum-progressive disease.
Camrelizumab is a programmed cell death 1 (PD-1) inhibitor currently undergoing phase 2 and 3 trials, and famitinib is a multitargeted receptor tyrosine kinase inhibitor that works to inhibit tumor growth to eventually result in tumor regression. Patients in the cohort who had progressed after platinum-based chemotherapy for advanced or metastatic disease, or who had progressed within 12 months of completing platinum-based neoadjuvant therapy, were given 200 mg of camrelizumab intravenously every two weeks, along with 20 mg of famitinib orally once a day.
In total, 36 patients were recruited for the cohort study. The median duration from enrollment to data cut-off was 11.9 months. The objective response rate was 30.6%, with median duration of response at 6.3 months, median progression-free survival at 4.1 months, and median overall survival at 12.9 months.
Bladder cancer patients had overall better outcomes, with an objective response rate of 38.9% and a median progression-free survival rate of 8.3 months. Out of the 36 patients, 22 exhibited grade 3 or 4 treatment-related adverse events, the most common of which were decreased platelet count and hypertension.
Camrelizumab combined with famitinib has been shown to provide potent antitumor activity in advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy, with bladder cancer patients exhibiting a better response to the drug combination.
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study